Securities code: 002432 securities abbreviation: Andon Health Co.Ltd(002432) Announcement No.: 2022-018 Andon Health Co.Ltd(002432)
Performance forecast for 2021
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and shall be jointly and severally liable for false records, misleading statements or major omissions in the announcement. 1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected operating performance: □ turn loss into profit √ increase in the same direction □ decrease in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to shareholders of listed companies: 90 million yuan profit: 242.3293 million yuan
Net profit – 120 million yuan
Year on year growth: 271.40%
—395.19%
Profit after deducting non recurring profit and loss: 850 million yuan – profit: 247483300 yuan
The net profit is 1150 million yuan
Year on year growth: 243.46%
—364.68%
Basic earnings per share: 1.9799 yuan / share to earnings: 0.56 yuan / share
RMB 2.6399/share
2、 Communication with accounting firms
The financial data related to this performance forecast has not been pre audited by an accounting firm. The company’s employment performance forecast has been pre communicated with the annual audit accounting firm, and there is no difference between the two sides.
3、 Explanation of performance change reasons
The company’s performance in 2021 is expected to increase compared with the same period last year. The main reasons are as follows:
2021 continues to be affected by the global COVID-19 epidemic, New Coronavirus (SARS-CoV-2)
The sales performance of antigen home self-test OTC kit products in the U.S. market increased significantly, which promoted the significant growth of business performance in 2021.
4、 Risk tips
This performance forecast is the result of preliminary calculation by the company’s financial department, and the specific financial data will be disclosed in detail in the company’s 2021 annual report. This performance forecast has not been audited by certified public accountants.
In 2021, the company’s operating performance mainly depends on covid-19 testing reagent. Whether the future performance can continue to maintain rapid growth is subject to major uncertainties, mainly depending on the progress of covid-19 epidemic prevention and control in the United States, the selection of covid-19 testing products in the United States, the company’s product market competitiveness and channel sales capacity, and the future development of conventional business, Please pay attention to investment risks.
It is hereby announced
Andon Health Co.Ltd(002432) board of directors
January 20, 2022
